

Clinical Trial Protocol

Iranian Registry of Clinical Trials

22 Jul 2026

Single-dose bioequivalence studies of Valsartan (80 mg) in healthy volunteers

Protocol summary

Study aim

Administration of test (generic) and reference (brand) products to healthy subjects Comparison of bioavailability and pharmacokinetics of two products Evaluation of interchangeability of two products

Design

This clinical trial study with control group was conducted on 26 patients with parallel, double-blind, random allocation, and bio-equivalence phase. 26 healthy volunteers after passing the inclusion and exclusion criteria will be divided into two groups of test and reference. Then, in the second period, the group that received the test drug will receive the reference drug and the other group will receive the test drug.

Settings and conduct

This study was single-dose, randomized, and crossover. In this way, after completing the consent form and being aware of the drug and its side effects, the candidates consume the test product in one period and the reference product in the other period. This study was conducted at Shahid Beheshti School of Pharmacy.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Healthy volunteers aged 18 to 50 years
Exclusion criteria: History of liver, kidney and cardiovascular diseases that can affect drug clearance from body History of taking any medication in the last two weeks Creatinine above 2

Intervention groups

Receiving test product Receiving reference product

Main outcome variables

The variables of this study include the maximum plasma concentration of the drug, the time to reach the maximum plasma concentration of the drug and the area below the concentration versus time curve. The first two variables are a measure of drug uptake rate and the third variable is a measure of drug uptake.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210201050197N2**

Registration date: **2021-03-01, 1399/12/11**

Registration timing: **registered_while_recruiting**

Last update: **2021-03-01, 1399/12/11**

Update count: **0**

Registration date

2021-03-01, 1399/12/11

Registrant information

Name

Azadeh Haeri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8820 0212

Email address

a_haeri@sbmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-02-26, 1399/12/08

Expected recruitment end date

2021-03-13, 1399/12/23

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Single-dose bioequivalence studies of Valsartan (80 mg) in healthy volunteers		Secondary ids	empty
Public title	Bioequivalence of Valsartan	Ethics committees	
Purpose	Other	1	
Inclusion/Exclusion criteria		Ethics committee	
Inclusion criteria:	Healthy volunteer Age: 18-50 year	Name of ethics committee	School of Pharmacy Nursing and Midwifery, Shahid Beheshti Medical University
Exclusion criteria:	History of liver, kidney and cardiovascular diseases that can affect drug clearance from body History of taking any medication in the last two weeks Creatinine above 2	Street address	No 2660, School of Pharmacy Nursing and Midwifery, Shahid Beheshti Medical University, Niayesh building, Valiasr Ave
Age	From 18 years old to 50 years old	City	Tehran
Gender	Both	Province	Tehran
Phase	Bioequivalence	Postal code	1996835113
Groups that have been masked	- Participant - Care provider	Approval date	2021-02-14, 1399/11/26
Sample size	Target sample size: 26	Ethics committee reference number	IR.SBMU.PHARMACY.REC.1399.341
Randomization (investigator's opinion)	Randomized	Health conditions studied	
Randomization description	In order to randomize, in this study, a random allocation rule has been used. For this purpose, first, a total sample size of volunteers who met the inclusion criteria was determined. In this way, 26 people who had passed the entry and exit criteria were selected and then assigned to each number by Excel program, and randomly 13 for the control group and 13 for the experimental group were selected. Then, by matching the number of people with their names, the two groups will be identified. Then, in the second period, the group that received the test drug received the reference drug and the other group received the test drug.	1	
Blinding (investigator's opinion)	Double blinded	Description of health condition studied	Healthy subjects
Blinding description	Candidates receive medication twice. Once Iranian product (generic) and once the foreign product (reference). Volunteers and study physicians are not aware of what products they have received at every turn. Because the medicine is taken out of its box and blister and given to the volunteers, they will have no knowledge of the type of medicine. The new drug is made in terms of color, smell, taste, consistency, and all appearance characteristics similar to the reference drug so that the participants are blind in this regard.	ICD-10 code	
Placebo	Not used	ICD-10 code description	
Assignment	Crossover	Primary outcomes	
Other design features		1	
		Description	Plasma drug concentration
		Timepoint	0.33, 0.66, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24 Hours
		Method of measurement	High performance liquid chromatography (HPLC) method
		Secondary outcomes	empty
		Intervention groups	
		1	
		Description	Intervention group: Receiving Iranian medicine (generic product): In this group, each volunteer receives a 80 mg Valsartan tablets made by Razak Company during a treatment period. After that, blood samples are taken from the volunteers for 24 hours. Blood samples (5 cc) are taken from volunteers at different times (14 times).

This completes a course of study. Pharmacokinetic parameters are calculated and compared by determining the drug concentration in blood samples by High-performance liquid chromatography (HPLC).

Category

Treatment - Drugs

2**Description**

Control group: Receiving reference medicine: In this group, each volunteer receives one reference tablet of 80 mg Valsartan in a course of treatment. After that, blood samples are taken from the volunteers for 24 hours. Blood samples (5 cc) are taken from volunteers at different times (14 times). This completes a course of study. Pharmacokinetic parameters are calculated and compared by determining the drug concentration in blood samples by High-performance liquid chromatography (HPLC).

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

School of Pharmacy, Shahid Beheshti University of Medical Sciences

Full name of responsible person

Azadeh Haeri

Street address

No 2660, School of Pharmacy Nursing and Midwifery, Shahid Beheshti Medical University, Niayesh building, Valiasr Ave

City

Tehran

Province

Tehran

Postal code

1996835113

Phone

+98 21 8820 0212

Email

a_haeri@sbmu.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Razak Pharmaceutical Company

Full name of responsible person

Ali Mortazavi

Street address

Km 10, Lashgari Expy, Tehran-IRAN

City

Tehran

Province

Tehran

Postal code

1389736615

Phone

+98 21 4456 7023

Email

info@razakpharma.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Razak Pharmaceutical Company

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Azadeh Haeri

Position

Assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No 2660, School of Pharmacy Nursing and Midwifery, Shahid Beheshti Medical University, Niayesh building, Valiasr Ave

City

Tehran

Province

Tehran

Postal code

1996835113

Phone

+98 21 8820 0212

Email

a_haeri@sbmu.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Azadeh Haeri

Position

Assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No 2660, School of Pharmacy Nursing and Midwifery,
Shahid Beheshti Medical University, Niayesh building,
Valiasr Ave

City

Tehran

Province

Tehran

Postal code

1996835113

Phone

+98 21 8820 0212

Email

a_haeri@sbm.u.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Azadeh Haeri

Position

Assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No 2660, School of Pharmacy Nursing and Midwifery,
Shahid Beheshti Medical University, Niayesh building,
Valiasr Ave

City

Tehran

Province

Tehran

Postal code

1996835113

Phone

+98 21 8820 0212

Email

a_haeri@sbm.u.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to
make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to
make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to
make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available